Aigen Investment Management LP Buys 7,598 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Aigen Investment Management LP boosted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,595 shares of the company’s stock after acquiring an additional 7,598 shares during the quarter. Aigen Investment Management LP’s holdings in Cellebrite DI were worth $1,159,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CLBT. FMR LLC lifted its position in Cellebrite DI by 136.3% in the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock valued at $94,586,000 after acquiring an additional 3,239,307 shares in the last quarter. True Wind Capital Management L.P. lifted its position in Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after buying an additional 2,130,386 shares in the last quarter. Principal Financial Group Inc. bought a new stake in Cellebrite DI during the 3rd quarter worth about $23,402,000. Lord Abbett & CO. LLC bought a new stake in Cellebrite DI during the 3rd quarter worth about $11,523,000. Finally, Summit Partners Public Asset Management LLC bought a new stake in Cellebrite DI during the 3rd quarter worth about $9,274,000. 45.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CLBT shares. Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Friday, February 14th. Craig Hallum boosted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $18.34 on Thursday. The firm’s 50-day moving average is $22.06 and its 200-day moving average is $19.68. The stock has a market cap of $3.78 billion, a price-to-earnings ratio of -13.19, a PEG ratio of 4.27 and a beta of 1.47. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.